Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : NOVARTIS
Femme et Homme Max 99 ans
NOVARTIS FARMA
MAJ Il y a 4 ans
A study to provide expanded access of Exjade deferasirox to patients with congenital disorders of red blood cells and chronic iron overload from blood transfusions who cannot adequately be treated with other locally approved iron chelators
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
NOVARTIS FARMA
MAJ Il y a 4 ans
A retrospective pharmacogenetic analysis of patients with elevated liver enzymes (Hy s law cases or AST/ALT > 10x ULN) in clinical studies CCOX189A0117, CCOX189A2332, CCOX189A2369, CCOX189A0126, CCOX189A0112, CCOX189A0109 or CCOX189A2361
The primary objective of this post-hoc pharmacogenetic sub-study is to determine whether patients who experienced severe hepatotoxicity when taking lumiracoxib are carriers of the DQA1*0102 allele.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
NOVARTIS FARMA
MAJ Il y a 4 ans
A randomized, open-label, controlled, multi-center two-year study comparing efficacy and safety of telbivudine LDT600 600 mg PO in combination with peg alpha-2a sq 180 g with peg alpha-2a monotherapy, and with telbivudine monotherapy in treatment na ve patients with HBeAg-positive compensated CHB
The primary objective of this study is to demonstrate the superior antiviral efficacy of the combination of peginterferon alpha-2a plus telbivudine vs. peginterferon alpha-2a monotherapy as demonstrat...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
NOVARTIS
MAJ Il y a 4 ans
Safety and Efficacy of APL180 in Healthy Volunteers and Patients With Coronary Heart Disease (CHD)
The purpose of this study is to determine: (1) the safety and pharmacokinetics of APL180 administered as a single intravenous infusion in healthy volunteers, and (2) the safety, pharmacoki...
Pays
Belgium
,
Denmark
,
Israel
,
Netherlands
,
South Africa
,
United Kingdom
,
United States
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
NOVARTIS FARMA
MAJ Il y a 4 ans
EVALUATION OF THE QUALITY OF LIFE AND GASTROINTESTINAL SYMPTOMS AFTER CONVERSION TO MYFORTIC (ERL080) and CELLCEPT WITHDRAWAL IN MAINTENANCE RENAL TRANSPLANT RECIPIENTS TREATED WITH TACROLIMUS
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
NOVARTIS FARMA
MAJ Il y a 4 ans
An extension of a clinical study to investigate long term safety of tobramycin inhalation powder (TIP) in patients with Cystic Fibrosis Estensione di uno studio clinico per valutare la sicurezza a lungo termine di tobramicina polvere per inalazione (Tobramycin Inhalation Powder – TIP) in pazienti con fibrosi cistica
To assess the safety of Tobramycin Inhalation Powder (TIP) across 12 treatment cycles (6 treatment cycles in the core study and 6 treatment cycles in the extension study) in terms of the incidence...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
NOVARTIS FARMA
MAJ Il y a 4 ans
A phase I/II open label, dose escalation trial to explore the safety and efficacy of ICL670 in patients with iron overload resulting from hereditary hemochromatosis
To explore the safety of ICL670 (dose range 5 to 20 mg/kg PO per day) in adult hemochromatosis patients homozygous for the C282Y mutation, with iron overload.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
NOVARTIS FARMA
MAJ Il y a 4 ans
An extension to a phase II open label study to determine the safety and anti-leukemic effects of STI571 in patients with Philadelphia chromosome positive chronic myeloid leukemia in myeloid blast crisis Estensione dello studio in aperto di fase II per determinare la tollerabilita` e l`efficacia antileucemica di STI571 in pazienti con leucemia mieloide cronica Ph+ in crisi blastica mieloide
To enable patients to have access to study drug and continue study treatment To decrease data collection to include only overall survival and serious adverse events Consentire ai pazienti ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
NOVARTIS FARMA
MAJ Il y a 4 ans
An open label, multicenter, pilot phase II study of SOM230 s.c. in patients with duodeno-pancreatic (neuro) endocrine tumors and different pituitary diseases (Nelsonメs syndrome, non-functioning adenoma, TSH-adenoma, Gonadotroph adenoma, and PRL-adenoma) with potential sensitivity to somatostatin analogues
To evaluate the effect of SOM230 s.c. in patients with rare life threatening diseases as follows: Biochemical tumor markers for those patients with duodeno-pancreatic (neuro) endocrine tumors (insuli...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
NOVARTIS FARMA
MAJ Il y a 4 ans
A 24-weeks , national, multicenter, double blind controlled vs placebo trial to evaluate the efficacy of Neoral ciclosporine 5mg/kg/day , twice a week administered in reduction of the rate of relapse in pz with chronic plaque psoriasis on remission. PREWENT Study
Relapse rate during the 24-weeks treatment with Neoral ciclosporine 5mg/kg/day twice a week
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Précédent
1
2
3
4
5
6
7
8
9
10
Suivant